Compare Chipotle Mexican Grill, Inc. (CMG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chipotle Mexican Grill, Inc. vs Sanofi SA — how do they compare? Chipotle Mexican Grill, Inc. trades at $32.62 (market cap $40.49B), while Sanofi SA trades at $43.6 (market cap $104.30B). The key difference: Sanofi SA is far larger — about 2.6× Chipotle Mexican Grill, Inc.'s market cap, and Sanofi SA pays a 5.55% dividend while Chipotle Mexican Grill, Inc. pays none. Which is the better fit depends on your goals.
| CMG | SNY | |
|---|---|---|
Market Cap | $40.49B | $104.30B |
Sector | Consumer Cyclical | Health |
52-Week High | $44.04 | $52.34 |
52-Week Low | $28.17 | $41.33 |
Enterprise Value | $45.24B | $124.19B |
Dividend Yield | — | 5.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Chipotle Mexican Grill (CMG) trades at $32.615, up 1.48% today, but faces headwinds from recent food safety concerns linked to salmonella outbreaks. The stock's technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported strong revenue growth to $11.93B in 2025 and a net income margin of 11.42%, though earnings face compression from rising costs. Recent news highlights ongoing litigation investigations and promotional efforts to boost customer engagement.
The investment outlook is mixed; analyst consensus remains bullish with a $42.17 price target, but near-term risks from food safety issues and margin pressures could limit upside. Long-term growth prospects are supported by consistent revenue increases, but investors should monitor resolution of health concerns and cost management.
SNY trades at $43.62, up 0.32% today, with a neutral technical signal and bullish moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and raised its 2026 outlook. Revenue for 2025 was $46.72B with net income of $7.81B, showing improved profitability. Analyst consensus is mixed with 44% Buy, 52% Hold, and 4% Sell ratings. Recent news highlights regulatory approvals for new drugs and pipeline developments under new CEO leadership.
The outlook for SNY is cautiously optimistic, driven by Dupixent's growth and new drug approvals, but faces risks from pipeline setbacks and competition. Earnings momentum and cost discipline support upside potential, though valuation multiples like a P/E of 23.27 may limit near-term gains. Key risks include biosimilar threats post-2031 and ongoing legal challenges. Institutional activity shows increased holdings, reflecting confidence in the company's strategic direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chipotle Mexican Grill, Inc.
Chipotle Mexican Grill is the largest fast-casual chain restaurant in the United States, with systemwide sales of $7.5 billion in 2021. The Mexican concept is entirely company-owned, with a footprint of more than 3,000 stores, heavily indexed to the United States (though the firm maintains a small presence in Canada, the U.K., France, and Germany). Chipotle sells burritos, burrito bowls, tacos, quesadillas, and beverages, with a selling proposition built around competitive prices, high-quality food sourcing, speed of service, and convenience. The company generates its revenue entirely from restaurant sales and delivery fees.
Read more on CMG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
